Abstract:Chimeric antigen receptor (CAR) T-cell therapy is an example of gene engineering-based cellular therapy, which combines immunotherapy, gene therapy, and cellular therapy. Historically, the second clinical trial of gene therapy for patients with haemophilia B was conducted by Chinese scientists in 1991, and China became the first country to approve a commercial gene therapy product in 2003. However, China almost lost its lead in this field, partly due to an early scarcity of clear and cohesive policies regarding cellular therapy. Cellular therapy is not only a novel medical practice but also a medicinal product. The increasing commercialisation of globally approved cell therapy products made the Chinese Government issue a series of relevant policies to promote the canonical development of cell therapy and its standardisation in China. Encouraged by flexible regulatory frameworks that have facilitated the development of cellular therapy since 2017, remarkable progress has been achieved, thereby putting China back at the forefront of the field worldwide. Some policies on cellular therapy launched by the Chinese government in 2019 have contributed to the growth of cellular therapy in China; however, the regulation, governance, and management of commercialised products remain challenging. This Series paper aims to provide an overview of the current regulatory reforms on clinical cellular therapy in China with a historical perspective. We also highlight several important contributors that could promote innovation and industrialisation of cellular therapy in China. Further efforts are needed to establish a legislative system with clear and cohesive policies for the increasing use of cellular therapy in China, enabling a more prescriptive, diligent, and informed process.

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy

CAR-T cells: the Chinese experience

CAR T-cell Therapies in China: Rapid Evolution and a Bright Future.

Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics

Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India

T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Clinical Development of CAR T Cell Therapy in China:2020 Update

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Identification of the Risks in CAR T-cell Therapy Clinical Trials in China: a Delphi Study.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?

Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the Sphinx?

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?